1. Home
  2. RGLS vs USAS Comparison

RGLS vs USAS Comparison

Compare RGLS & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • USAS
  • Stock Information
  • Founded
  • RGLS 2007
  • USAS 1998
  • Country
  • RGLS United States
  • USAS Canada
  • Employees
  • RGLS N/A
  • USAS N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • USAS Metal Mining
  • Sector
  • RGLS Health Care
  • USAS Basic Materials
  • Exchange
  • RGLS Nasdaq
  • USAS Nasdaq
  • Market Cap
  • RGLS 102.1M
  • USAS 122.4M
  • IPO Year
  • RGLS 2012
  • USAS N/A
  • Fundamental
  • Price
  • RGLS $1.55
  • USAS $0.40
  • Analyst Decision
  • RGLS Strong Buy
  • USAS Strong Buy
  • Analyst Count
  • RGLS 6
  • USAS 1
  • Target Price
  • RGLS $10.33
  • USAS $0.80
  • AVG Volume (30 Days)
  • RGLS 268.2K
  • USAS 575.2K
  • Earning Date
  • RGLS 11-07-2024
  • USAS 11-07-2024
  • Dividend Yield
  • RGLS N/A
  • USAS N/A
  • EPS Growth
  • RGLS N/A
  • USAS N/A
  • EPS
  • RGLS N/A
  • USAS N/A
  • Revenue
  • RGLS N/A
  • USAS $97,123,000.00
  • Revenue This Year
  • RGLS N/A
  • USAS $21.84
  • Revenue Next Year
  • RGLS N/A
  • USAS $46.00
  • P/E Ratio
  • RGLS N/A
  • USAS N/A
  • Revenue Growth
  • RGLS N/A
  • USAS 14.33
  • 52 Week Low
  • RGLS $1.08
  • USAS $0.20
  • 52 Week High
  • RGLS $3.79
  • USAS $0.54
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 49.06
  • USAS 53.40
  • Support Level
  • RGLS $1.49
  • USAS $0.35
  • Resistance Level
  • RGLS $1.62
  • USAS $0.41
  • Average True Range (ATR)
  • RGLS 0.11
  • USAS 0.02
  • MACD
  • RGLS -0.00
  • USAS 0.00
  • Stochastic Oscillator
  • RGLS 37.50
  • USAS 61.00

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About USAS Americas Gold and Silver Corporation no par value

Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets are The Cosala operations, The Galena Complex, and Relief Canyon. The company also holds interests in the San Felipe Development Project located in Sonora, Mexico. It has geographic focus is the Western Hemisphere, particularly the United States and Mexico.

Share on Social Networks: